Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic...

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Endothelial dysfunction is a key prognostic indicator in heart failure (HF).
• Statins, including atorvastatin, offer benefits beyond lipid reduction, particularly in atherosclerotic conditions.
• Understanding atorvastatin's impact on endothelial function and progenitor cells in HF is crucial for treatment optimization.

Purpose of the Study:

• To investigate the effects of low and intermediate doses of atorvastatin on endothelial function.
• To assess the impact of atorvastatin on the mobilization of bone marrow-derived endothelial progenitor cells (EPCs).
• To evaluate changes in inflammatory status in heart failure patients treated with atorvastatin.

Main Methods:

• A randomized, double-blind, cross-over study involving 26 ischemic heart failure patients.
• Administration of atorvastatin at 40 mg/day and 10 mg/day for 4 weeks each.
• Evaluation of circulating CD34(+)/CD133(+)/KDR(+) EPCs via flow cytometry, endothelial function by flow-mediated dilation (FMD), and serum TNF-α levels by ELISA.

Main Results:

• Both 40 mg/day and 10 mg/day atorvastatin significantly increased circulating EPCs and reduced TNF-α levels compared to baseline.
• Atorvastatin treatment significantly improved flow-mediated dilation (FMD) at the 40 mg/day dose.
• A greater increase in EPCs was observed in NYHA class II patients compared to NYHA class III patients with 40 mg/day atorvastatin.

Conclusions:

• Atorvastatin treatment effectively restores endothelial function through enhanced EPC mobilization in ischemic heart failure.
• The findings suggest that monitoring EPC status can aid in individualizing atorvastatin treatment strategies for HF patients.
• Atorvastatin demonstrates pleiotropic effects beneficial for cardiovascular health in HF patients.